Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cluster of Differentiation 52 (CD52)
- Target
- CD52
- Molecular classification
- Glycoprotein, GPI-anchored protein
01
Overview
CD52 is a small, heavily glycosylated glycoprotein anchored to the cell surface via a GPI linkage. It is highly expressed on mature lymphocytes, monocytes, eosinophils, neutrophils, and spermatozoa. While its precise physiological function is not fully understood, it plays a role in immune regulation, antiadhesion, and complement inhibition. CD52 is a therapeutic target for monoclonal antibody therapies like alemtuzumab, which is used to treat certain leukemias, lymphomas, and multiple sclerosis by inducing immune suppression through the depletion of CD52-expressing cells.
- Other names
- CAMPATH-1 antigenCDW52EDDM5HE5gp20
02
Mechanism of action
Alemtuzumab binds to CD52, leading to complement-mediated lysis and antibody-dependent cellular cytotoxicity of CD52-expressing cells.
03
Biological functions
Immune regulationAntiadhesionComplement inhibitionModulation of inflammation
04
Disease associations
LeukemiaLymphomaMultiple SclerosisMyelodysplastic SyndromesAcute Myeloid Leukemia
05
Safety considerations
Immune suppressionIncreased risk of infectionInfusion-related reactions
06
Interacting drugs
Alemtuzumab (CAMPATH)
Beyond the preview
Go deeper on Cluster of Differentiation 52 (CD52).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cluster of Differentiation 52 (CD52).